ASCO20: Why has non-metastatic castration-resistant prostate cancer become interesting?

Eric Small | ASCO20 Virtual | Onkologia ja Hematologia | KESÄKUU 9, 2020

Asiantuntija: Eric Small

Listen to Eric J. Small, MD and principal investigator of the SPARTAN study, explain why non-metastatic castration-resistant prostate cancer (nmCRPC) has become relevant. The SPARTAN study has investigated the efficiency and safety of apalutamide for patients with nmCRPC.